Ideaya Biosciences

This early-stage trial tests a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in 216 adults with advanced solid tumors (like breast, ovarian, or lung cancer). The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. It i…

This phase 2 trial tests the drug darovasertib in 160 people with uveal melanoma, a rare eye cancer. The drug is given before and after standard treatments like surgery or radiation. The main goals are to see if it can help some patients avoid eye removal, reduce radiation needed…

This early-phase study tests an experimental drug called IDE397 in adults with advanced solid tumors that have a specific genetic change (MTAP deletion) and have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumor…

This study tests a new combination of two drugs (IDE196 and crizotinib) against standard treatments for people with a rare eye cancer called uveal melanoma that has spread to other parts of the body. It includes 420 adults whose cancer cells lack a specific marker (HLA-A2 negativ…